Canntab Therapeutics Limited Stock Net Income
| CTABFDelisted Stock | USD 0.0001 0.00 0.00% |
Canntab Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Canntab Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Canntab Therapeutics' valuation are provided below:Canntab Therapeutics Limited does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Canntab |
Search Suggestions
| CTA | Simplify Managed Futures | ETF |
| CTAS | Cintas | Company |
| CTA-PA | E I du | Company |
| CTAKX | American Funds College | Mutual Fund |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Canntab Therapeutics Limited reported net income of (3.69 Million). This is 101.08% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 100.65% higher than that of the company.
Canntab Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Canntab Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Canntab Therapeutics could also be used in its relative valuation, which is a method of valuing Canntab Therapeutics by comparing valuation metrics of similar companies.Canntab Therapeutics is currently under evaluation in net income category among its peers.
Canntab Fundamentals
| Return On Equity | -6.02 | |||
| Return On Asset | -0.82 | |||
| Operating Margin | (26.95) % | |||
| Current Valuation | 1.73 M | |||
| Shares Outstanding | 38.91 M | |||
| Shares Owned By Insiders | 15.08 % | |||
| Price To Book | 4.74 X | |||
| Price To Sales | 1.83 X | |||
| Revenue | 293.36 K | |||
| Gross Profit | (939.01 K) | |||
| EBITDA | (2.49 M) | |||
| Net Income | (3.69 M) | |||
| Cash And Equivalents | 691.11 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 126.2 K | |||
| Debt To Equity | 2.43 % | |||
| Current Ratio | 0.57 X | |||
| Book Value Per Share | (0.04) X | |||
| Cash Flow From Operations | (2.85 M) | |||
| Earnings Per Share | (0.1) X | |||
| Beta | 0.9 | |||
| Market Capitalization | 774.29 K | |||
| Total Asset | 2.85 M | |||
| Z Score | 3.6 | |||
| Net Asset | 2.85 M |
About Canntab Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Canntab Therapeutics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Canntab Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Canntab Therapeutics Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Canntab Pink Sheet
If you are still planning to invest in Canntab Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Canntab Therapeutics' history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |